Data on pilot assessment of efficacy of artemether lumefantrine when co-administered with ciprofloxacin in malaria-typhoid co-infected patients.

Malaria -typhoid co-infection is associated with poverty and underdevelopment with significant morbidity and mortality with similarities in clinical features of the two diseases that often result in misdiagnosis and mistreatment of the febrile patients. The Co-administration of artemether lumefantrine (AL) with ciprofloxacin as treatment for malaria-typhoid co-infection is common in Nigeria and this increases risk of pharmacokinetic drug-drug interaction since ciprofloxacin is an inhibitor of CYP3A4 that metabolizes AL. In an open-label prospective three arm design with registration pactr201909811770922, one hundred and nineteen (119) febrile volunteers comprising 55 males and 64 females were distributed into three oral treatment regimen groups. Group 1 consist of sixty-five participants presenting malaria mono infection treated with AL only and fifty-four participants presenting malaria-typhoid co-infection randomly assigned to Group 2 treated with AL and ciprofloxacin concomitantly and Group 3 whose doses were staggered at 2 hours interval. Blood samples were collected from participants in the three groups on 3 different days: day 0 (before commencement of treatment); day 3 (after completion of AL); and day 7 (after completion of ciprofloxacin), The collected blood sample were used to determine parasite density, serum liver and kidney function parameters, haematological indices, and day 7 lumefantrine concentration. The data in this article provides the changes in PCR-uncorrected Early Treatment Failure (ETA), Late Clinical Failure (LCF), Late Parasitological Failure (LPF), Day 7 serum lumefantrine concentration, liver and kidney function parameters, axillary body temperature and PCV/Hb associated with the different treatment regimen. The dataset [1] as a baseline, will stimulate the need for a randomized clinical assessment of the efficacy of AL when co-administered with ciprofloxacin in the treatment regimen of Malaria-typhoid co-infection in endemic areas. Such findings are capable of influencing national treatment policy on the management of malaria-typhoid co-infection.

RCT Entities:   Population Interventions Outcomes